Researchers identify 'switch' to activate cancer cell death

byUC DavisAntigen-positive tumor cell (blue, left) is a direct target of CAR T-cells (light red) due to high-affinity antibody-antigen contacts. On the contrary, an antigen-negative tumor cell (

Updated on: October 31,2023

Researchers identify 'switch' to activate cancer cell death

byUC DavisAntigen-positive tumor cell (blue, left) is a direct target of CAR T-cells (light red) due to high-affinity antibody-antigen contacts. On the contrary, an antigen-negative tumor cell (

Updated on:October 31,2023

Atezolizumab Plus Bevacizumab and Chemotherapy Fails to Provide PFS Benefit in Platinum-Sensitive

September 13, 2023Kyle DohertyThe addition of the PD-L1 inhibitor atezolizumab to bevacizumab and platinum-based chemotherapy did not result in a statistically significant progression-free survival be

Updated on: October 11,2023

Atezolizumab Plus Bevacizumab and Chemotherapy Fails to Provide PFS Benefit in Platinum-Sensitive

September 13, 2023Kyle DohertyThe addition of the PD-L1 inhibitor atezolizumab to bevacizumab and platinum-based chemotherapy did not result in a statistically significant progression-free survival be

Updated on:October 11,2023

Trial supports radiotherapy and cisplatin remaining as the standard of care for p16+ oropharyngeal cancer

by NRG OncologyCredit: Pixabay/CC0 Public DomainThe NRG Oncology NRG-HN005 phase II/III clinical trial has not met the non-inferiority criteria to proceed to the phase III portion of the study. The ph

Updated on: October 21,2024

Trial supports radiotherapy and cisplatin remaining as the standard of care for p16+ oropharyngeal cancer

by NRG OncologyCredit: Pixabay/CC0 Public DomainThe NRG Oncology NRG-HN005 phase II/III clinical trial has not met the non-inferiority criteria to proceed to the phase III portion of the study. The ph

Updated on:October 21,2024

Targeting menin induces responses in acute leukemias with KMT2A rearrangements or NPM1 mutations

byUniversity of Texas M. D. Anderson Cancer CenterBone marrow aspirate showing acute myeloid leukemia. Several blasts have Auer rods. Credit: WikipediaResearchers from The University of Texas MD

Updated on: December 19,2023

Targeting menin induces responses in acute leukemias with KMT2A rearrangements or NPM1 mutations

byUniversity of Texas M. D. Anderson Cancer CenterBone marrow aspirate showing acute myeloid leukemia. Several blasts have Auer rods. Credit: WikipediaResearchers from The University of Texas MD

Updated on:December 19,2023

AstraZeneca to Discontinue Moxetumomab Pasudotox in US for Hairy Cell Leukemia

January 13, 2023Chris RyanMoxetumomab pasudotox-tdfk will be permanently discontinued in the United States market for the treatment of relapsed/refractory hairy cell leukemia.Hairy Cell Leukemia (Kate

Updated on: October 15,2023

AstraZeneca to Discontinue Moxetumomab Pasudotox in US for Hairy Cell Leukemia

January 13, 2023Chris RyanMoxetumomab pasudotox-tdfk will be permanently discontinued in the United States market for the treatment of relapsed/refractory hairy cell leukemia.Hairy Cell Leukemia (Kate

Updated on:October 15,2023

New biomarker advances cancer treatments

Researchers have discovered ways to enhance NIR-PIT to ensure tumours are treated sufficiently and improve patient outcomes.A biomarker based on microbubbles has been used to evaluate the success of n

Updated on: November 21,2023

New biomarker advances cancer treatments

Researchers have discovered ways to enhance NIR-PIT to ensure tumours are treated sufficiently and improve patient outcomes.A biomarker based on microbubbles has been used to evaluate the success of n

Updated on:November 21,2023

Discovery suggests new way to target mantle cell lymphoma

byWeill Cornell Medical CollegeThe interaction of two proteins required to regulate expression of key genes in the nucleus of mantle cell lymphoma. The red signals are generated at the interacti

Updated on: December 21,2023

Discovery suggests new way to target mantle cell lymphoma

byWeill Cornell Medical CollegeThe interaction of two proteins required to regulate expression of key genes in the nucleus of mantle cell lymphoma. The red signals are generated at the interacti

Updated on:December 21,2023

Imaging technique can observe specialized cancer treatment in breast cancer models

byJohns Hopkins University School of MedicineCredit: Unsplash/CC0 Public DomainFor nearly a century, scientific evidence has shown that the use of specific bacteria to target cancer tumors and t

Updated on: October 31,2023

Imaging technique can observe specialized cancer treatment in breast cancer models

byJohns Hopkins University School of MedicineCredit: Unsplash/CC0 Public DomainFor nearly a century, scientific evidence has shown that the use of specific bacteria to target cancer tumors and t

Updated on:October 31,2023

Rise in skin cancer cases underscores importance of early detection using machine learning

In a recent review published in theLifeJournal, a group of authors reviewed image-processing techniques in machine learning (ML) for skin cancer detection using clinical images, evaluating

Updated on: October 31,2023

Rise in skin cancer cases underscores importance of early detection using machine learning

In a recent review published in theLifeJournal, a group of authors reviewed image-processing techniques in machine learning (ML) for skin cancer detection using clinical images, evaluating

Updated on:October 31,2023

Key Factors to Consider in the Management of Tumor Lysis Syndrome

February 22, 2023Brittany LovelyFor patients with aggressive malignant tumors and high tumor burden, onco- logic emergencies such as tumor lysis syndrome emerge as a disease symptom or a treat- ment-r

Updated on: October 15,2023

Key Factors to Consider in the Management of Tumor Lysis Syndrome

February 22, 2023Brittany LovelyFor patients with aggressive malignant tumors and high tumor burden, onco- logic emergencies such as tumor lysis syndrome emerge as a disease symptom or a treat- ment-r

Updated on:October 15,2023

Long-Term Data Sustain Dabrafenib/Trametinib RFS Benefit in BRAF+ Melanoma

October 22, 2018Onclive TeamLong-term follow-up from the COMBI-AD trial continued to show a significant relapse-free survival advantage for patients with resected stage III BRAF-mutant melanoma treate

Updated on: October 24,2023

Long-Term Data Sustain Dabrafenib/Trametinib RFS Benefit in BRAF+ Melanoma

October 22, 2018Onclive TeamLong-term follow-up from the COMBI-AD trial continued to show a significant relapse-free survival advantage for patients with resected stage III BRAF-mutant melanoma treate

Updated on:October 24,2023

Trabectedin/Durvalumab Shows Early Activity, Demonstrates Feasibility for Soft Tissue Sarcoma

September 21, 2020Nichole Tuckerhe feasibility of treatment with trabectedin in combination with durvalumab as treatment of patients with advanced or metastatic pretreated soft tissue sarcoma was demo

Updated on: October 24,2023

Trabectedin/Durvalumab Shows Early Activity, Demonstrates Feasibility for Soft Tissue Sarcoma

September 21, 2020Nichole Tuckerhe feasibility of treatment with trabectedin in combination with durvalumab as treatment of patients with advanced or metastatic pretreated soft tissue sarcoma was demo

Updated on:October 24,2023